Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
APL-2 demonstrated positive preliminary results across key renal measures including a nearly 50% reduction in proteinuria
CRESTWOOD, Ky., and WALTHAM Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced positive preliminary results in the C3 glomerulopathy (C3G) cohort of the Phase 2 DISCOVERY study. The data showed that APL-2 (pegcetacoplan), an investigational C3-targeted inhibitor, may have the potential to target the underlying disease process of C3G. Results through study day 84 (12 weeks) were presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington D.C., and based on these results, Apellis plans to advance development of APL-2 in C3G.
In the data presented on six C3G patients treated with APL-2, there was a downward trend in mean proteinuria as measured by the urine protein-to-creatinine ratio (uPCR). Mean (SE) uPCR decreased from 2.03 (0.46) mg/mg to 1.05 (0.23) mg/mg at study day 84 (normal range
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.